CancerNetwork® sat down with Alicia Morgans MD, MPH, at the 2021 European Society for Medical Oncology to discuss how a hypothetical cohort from the CARD trial highlighted the impact of treatment with cabazitaxel on costs and complications in patients with metastatic castration-resistant prostate cancer.
At the 2021 European Society of Medical Oncology Congress, CancerNetwork® spoke with Alicia Morgans, MD, MPH, director of Survivorship Program at Dana-Farber Cancer Institute, about a hypothetical cohort included in the phase 4 CARD trial (NCT02485691).
In addition to highlighting how findings from the cohort shed light on the impact of cabazitaxel (Jevtana) on the costs and complications that patients with metastatic castration-resistant prostate cancer may experience, as well as utilizing this information to better help patients.
We did observe that patients who were treated with cabazitaxel had fewer skeletal-related events, which was very important. The CARD study showed the differences in safety, and in this hypothetical cohort, what we did was apply the differences that already existed within that phase 4 trial to a population of patients. [This was] not to look for new differences, but to understand how that would impact patients in terms of hospital days, ICU days, and cost of care. We weren’t redefining rates of complication, but really taking the known rates from the trial and putting them into context in this setting.
Morgans AK, Hutson TE, Guan AK, et al. Clinical and cost impact of cabazitaxel versus (vs) a second androgen receptor targeted agent (ARTA) for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel and the alternative ARTA (abiraterone or enzalutamide). Presented at: 2021 European Society of Medical Oncology Congress; September 16-21, 2021; Virtual. Abstract 587P.